Vera Therapeutics, INC Form 4 insider transactions

Director Beth C. Seidenberg of Vera Therapeutics, Inc. sold shares of Class A Common Stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce, CEO of Vera Therapeutics, reports the sale of common stock and exercise of stock options on October 23, 2024, according to a Form 4 filing with the SEC.

Marshall Fordyce, CEO of Vera Therapeutics, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce, CEO of Vera Therapeutics, exercised stock options and sold shares of Class A Common Stock on September 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Beth C. Seidenberg sold shares of Vera Therapeutics (VERA) on September 18 and 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce, CEO of Vera Therapeutics, exercised stock options and sold shares of Class A Common Stock on September 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vera Therapeutics CEO Marshall Fordyce exercised stock options and sold shares of Class A Common Stock on August 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vera Therapeutics CEO Marshall Fordyce sold 14,471 shares of Class A Common Stock on August 21, 2024, to cover tax withholding obligations.

Vera Therapeutics CEO Fordyce Marshall exercised stock options and sold shares of Class A Common Stock on August 14, 2024, according to a Form 4 filing with the SEC.

David Lee Johnson, COO of Vera Therapeutics, acquired 160,000 stock options on July 1, 2024, according to a Form 4 filing.

Christy J. Oliger, a director at Vera Therapeutics, acquired 25,000 stock options on June 7, 2024, according to a Form 4 filing with the SEC.

Joseph R. Young, SVP of Finance and Chief Accounting Officer at Vera Therapeutics, reports the sale of company stock and the exercise of stock options.

Director Beth C. Seidenberg acquired stock options for 14,000 shares of Vera Therapeutics, Inc. at an exercise price of $42.69 on May 15, 2024.

Director Scott W. Morrison acquired 14,000 stock options in Vera Therapeutics, Inc. on May 15, 2024.

Michael Morrissey, a director of Vera Therapeutics, acquired 14,000 stock options at an exercise price of $42.69 on May 15, 2024.

Director Maha Katabi acquired 14,000 stock options in Vera Therapeutics, Inc. on May 15, 2024.

Director Kimball Hall of Vera Therapeutics, Inc. reports the acquisition of stock options.

Patrick G. Enright, a director of Vera Therapeutics, acquired 14,000 stock options on May 15, 2024, according to a recent SEC filing.

Director Andrew Cheng acquired 14,000 stock options in Vera Therapeutics, Inc. on May 15, 2024.

Joseph R. Young, SVP, Finance, Chief Accounting Officer of Vera Therapeutics, sold 5,714 shares of Class A Common Stock at $40 per share on April 10, 2024.

Sean Grant, CFO of Vera Therapeutics, exercised stock options and sold a significant number of shares on April 3, 2024, according to a Form 4 filing with the SEC.

Sean Grant, CFO of Vera Therapeutics, reports changes in beneficial ownership of Class A Common Stock due to gifts and transactions through trusts and custodial accounts.

Director Maha Katabi, associated with Sofinnova Venture Partners, reports the sale of Vera Therapeutics (VERA) shares between March 21 and March 25, 2024.